Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand
PR92818
GAITHERSBURG, Md., Nov. 4, 2021 /PRNewswire=KYODO JBN/ --
- Submission to New Zealand's Medsafe marks the first protein-based COVID-19
vaccine submitted for authorization to regulatory authorities in New Zealand
- All modules required for regulatory review of Novavax vaccine, including CMC
data, are now complete for Medsafe
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing
and commercializing next-generation vaccines for serious infectious diseases,
today announced the company has filed for provisional approval of the vaccine
to the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).
"Today's submission marks Novavax' continued progress in bringing the first
protein-based COVID-19 vaccine based on phase 3 data to the global community,"
said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We
remain laser-focused on delivering our vaccine, which is built on a proven,
well-understood vaccine platform, and thank the Government of New Zealand for
their ongoing partnership and confidence in our COVID-19 vaccine program."
Novavax has now completed the submission to Medsafe of all modules required for
the regulatory evaluation of NVX-CoV2373, a recombinant nanoparticle
protein-based COVID-19 vaccine with Matrix-M(TM) adjuvant. The chemistry,
manufacturing and controls (CMC) module submitted to Medsafe, as well as other
regulatory agencies worldwide, leverage Novavax' manufacturing partnership with
the Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine
manufacturer by volume. It will later be supplemented with data from additional
manufacturing sites in Novavax' global supply chain.
The submission includes clinical data from PREVENT-19, a pivotal Phase 3 trial
of 30,000 participants in the U.S. and Mexico that demonstrated 100% protection
against moderate and severe disease and 90.4% efficacy overall. Clinical data
from a pivotal Phase 3 trial of 15,000 participants in the U.K. were also
previously submitted to Medsafe, in which NVX-CoV2373 demonstrated efficacy of
96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7)
variant and 89.7% efficacy overall. In both trials, NVX-CoV2373 demonstrated a
favorable safety and tolerability profile.
 
Novavax recently announced regulatory filings for its vaccine in the United
Kingdom (https://c212.net/c/link/?t=0&l=en&o=3345896-1&h=393088484&u=https%3A%2F%2Fir.novavax.com%2F2021-10-27-Novavax-Files-for-Authorization-of-its-COVID-19-Vaccine-in-the-United-Kingdom&a=United+Kingdom), Australia (https://c212.net/c/link/?t=0&l=en&o=3345896-1&h=1077431467&u=https%3A%2F%2Fir.novavax.com%2F2021-10-29-Novavax-Files-for-Provisional-Approval-of-its-COVID-19-Vaccine-in-Australia&a=Australia), and Canada, and the completion of all data and modules in the European Union
(https://c212.net/c/link/?t=0&l=en&o=3345896-1&h=3057253372&u=https%3A%2F%2Fir.novavax.com%2F2021-11-01-Novavax-Files-for-COVID-19-Vaccine-Authorization-with-Health-Canada-and-Completes-Submission-for-Rolling-Review-to-European-Medicines-Agency&a=Canada%2C+and+the+completion+of+all+data+and+modules+in+the+European+Union). The company also expects to complete an additional supplemental filing for
its vaccine for Emergency Use Listing with the World Health Organization
shortly. Novavax expects to submit the complete package to the U.S. FDA by the
end of the year.
This submission was facilitated by the company's local partner, Biocelect Pty.
Ltd., as sponsor.
About the NVX-CoV2373 Phase 3 trials
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the
U.K. that demonstrated efficacy of 96.4% against the original virus strain,
86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; and the
PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection
against moderate and severe disease and 90.4% efficacy overall. It was
generally well-tolerated and elicited a robust antibody
response.
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic
sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19
disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle
technology to generate antigen derived from the coronavirus spike (S) protein
and is formulated with Novavax' patented saponin-based Matrix-M(TM) adjuvant to
enhance the immune response and stimulate high levels of neutralizing
antibodies. NVX-CoV2373 contains purified protein antigen and can neither
replicate, nor can it cause COVID-19.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a
vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses
(5 microgram antigen and 50 microgram Matrix-M adjuvant) given intramuscularly
21 days apart. The vaccine is stored at 2 degrees – 8 degrees Celsius, enabling
the use of existing vaccine supply and cold chain channels.
About Matrix-M(TM) Adjuvant
Novavax' patented saponin-based Matrix-M(TM) adjuvant has demonstrated a potent
and well-tolerated effect by stimulating the entry of antigen-presenting cells
into the injection site and enhancing antigen presentation in local lymph
nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved
health globally through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The company's
proprietary recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. Novavax is conducting
late-stage clinical trials for NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase
3 clinical trial in older adults. Both vaccine candidates incorporate Novavax'
proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response
and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter (https://c212.net/c/link/?t=0&l=en&o=3345896-1&h=1311999227&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3260461-1%26h%3D1316526774%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3158017-1%2526h%253D500821283%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252FNovavax%2526a%253DTwitter%26a%3DTwitter&a=Twitter) and LinkedIn (https://c212.net/c/link/?t=0&l=en&o=3345896-1&h=909592108&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3260461-1%26h%3D1508558197%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3158017-1%2526h%253D3702938248%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fnovavax%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&a=LinkedIn).
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and
prospects, its partnerships, the ongoing development of NVX-CoV2373 and other
Novavax vaccine product candidates, and the scope, timing and outcome of future
regulatory filings are forward-looking statements. Novavax cautions that these
forward-looking statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include challenges
satisfying, alone or together with partners, various safety, efficacy, and
product characterization requirements, including those related to process
qualification and assay validation, necessary to satisfy applicable regulatory
authorities; difficulty obtaining scarce raw materials and supplies; resource
constraints, including human capital and manufacturing capacity, on the ability
of Novavax to pursue planned regulatory pathways; challenges meeting
contractual requirements under agreements with multiple commercial,
governmental, and other entities; and those other risk factors identified in
the "Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Novavax' Annual Report on Form
10-K for the year ended December 31, 2020 and subsequent Quarterly Reports on
Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We
caution investors not to place considerable reliance on forward-looking
statements contained in this press release. You are encouraged to read our
filings with the SEC, available at www.sec.gov and www.novavax.com, for a
discussion of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the statements. Our
business is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | +1 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | +1 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | +1 240-720-7804
Laura Keenan Lindsey | +1 202-709-7521
media@novavax.com
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
SOURCE Novavax, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。